Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study

European Review for Medical and Pharmacological Sciences

Volumn 11, Issue 3, 2007, Pages 179-184

  De Angelis, S ^a   Noce, A ^a   Di Renzo, L ^a   Cianci, R ^a,c   Naticchia, A ^a   Giarrizzo, G F ^a   Giordano, F ^b   Tozzo, C ^a   Splendiani, G ^a   De Lorenzo, Antonino ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Division of Nephrology   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Allopurinol; Chronic renal failure; Hyperuricemia; Recombinant urate oxidase

Indexed keywords

ALLOPURINOL; CREATININE; ESTROGEN; NITROGEN; RASBURICASE; RECOMBINANT ENZYME; RECOMBINANT URATE OXIDASE; UNCLASSIFIED DRUG; UREA; URIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HYPERURICEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; CREATININE; DOUBLE-BLIND METHOD; FEMALE; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; TREATMENT OUTCOME; URATE OXIDASE; URIC ACID;

EID: 34547485447     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. VAZIRI ND, FREEL RW, HATCH M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995; 6: 1313-1317.
2. VIAZZI F, PARODI D, LEONCINI G, PARODI A, FALQUI V, RATTO E, VETTORETTI S, BEZANTE GP, DEL SETTE M, DE FERRARI G, PONTREMOLI R. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991-996.
3. KANG DH, NAGAKAWA T, FENG L, WATANABE S, HAN L, MAZZALI M, TRUONG L, HARRIS R, RICHARD JOHNSON. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897.
4. ISEKI K, OSHIRO S, TOZAWA M, ISEKI C, IKEMIYA Y, TAKISHITA S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001; 24: 691-697.
5. FEIG DI, MAZZALI M, KANG DH, NAKAGAWA T, PRICE K, KANNELIS J, JOHNSON RJ. Serum uric acid: A risk factor and a target for treatment? J Am Soc Nephrol 2006; 17: S69-S73.
6. SCHLESINGER N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64: 2399-2416.
7. PUI CH. Rasburicase: A potent uricolytic agent. Expert Opin Pharmacother 2002; 3: 433-452.
8. CANNELLA AC, MIKULS TR. Understanding treatments for gout. Am J Manag Care 2005; 11: S451-458.
9. SIU YP, LEUNG KT, KA-HANG TONG M, KWAN TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.